---
title: Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic
  Leukemia
date: '2025-02-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39976417/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20250221170838&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Acalabrutinib-venetoclax with or without obinutuzumab significantly
  prolonged progression-free survival as compared with chemoimmunotherapy in fit patients
  with previously untreated CLL. (Funded by AstraZeneca; AMPLIFY ClinicalTrials.gov
  number, ...'
disable_comments: true
---
CONCLUSIONS: Acalabrutinib-venetoclax with or without obinutuzumab significantly prolonged progression-free survival as compared with chemoimmunotherapy in fit patients with previously untreated CLL. (Funded by AstraZeneca; AMPLIFY ClinicalTrials.gov number, ...